Simonetta Viviani
About
Simonetta Viviani is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Simonetta Viviani has authored 119 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Pathology and Forensic Medicine, 41 papers in Oncology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Simonetta Viviani's work include Lymphoma Diagnosis and Treatment (85 papers), Lung Cancer Treatments and Mutations (35 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Simonetta Viviani is often cited by papers focused on Lymphoma Diagnosis and Treatment (85 papers), Lung Cancer Treatments and Mutations (35 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Simonetta Viviani collaborates with scholars based in Italy, United States and France. Simonetta Viviani's co-authors include V. Bonfante, Gianni Bonadonna, Pinuccia Valagussa, Armando Santoro, Liliana Devizzi, G. Ragni, Alessandro M. Gianni, O Bestetti, Anna Russo and Andrea Gallamini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Simonetta Viviani
115 papers receiving 4.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Simonetta Viviani Italy | 33 | 3.2k | 1.9k | 1.2k | 1.2k | 755 | 119 | 4.4k | ||
| Eva Cavallin‐Ståhl Sweden | 39 | 1.3k 0.4× | 1.3k 0.7× | 584 0.5× | 1.0k 0.9× | 601 0.8× | 119 | 4.6k | ||
| Francesco d’Amore Denmark | 35 | 4.4k 1.4× | 2.4k 1.3× | 1.1k 0.9× | 1.2k 1.1× | 835 1.1× | 175 | 5.7k | ||
| Peter Borchmann Germany | 45 | 4.5k 1.4× | 3.5k 1.9× | 1.5k 1.3× | 1.2k 1.0× | 1.0k 1.4× | 305 | 7.1k | ||
| Michael L. Grossbard United States | 37 | 1.8k 0.6× | 2.3k 1.2× | 509 0.4× | 981 0.8× | 859 1.1× | 120 | 4.7k | ||
| A. Z. S. Rohatiner United Kingdom | 43 | 4.2k 1.3× | 3.1k 1.7× | 637 0.5× | 760 0.6× | 2.1k 2.8× | 117 | 6.8k | ||
| Franca Fossati‐Bellani Italy | 29 | 1.2k 0.4× | 1.2k 0.6× | 897 0.8× | 1.4k 1.2× | 703 0.9× | 83 | 4.3k | ||
| Gustaaf W. van Imhoff Netherlands | 31 | 2.3k 0.7× | 1.9k 1.0× | 732 0.6× | 235 0.2× | 979 1.3× | 84 | 3.6k | ||
| Arne Kolstad Norway | 28 | 2.1k 0.7× | 1.9k 1.0× | 270 0.2× | 522 0.4× | 908 1.2× | 121 | 3.5k | ||
| J. Rosenberg United States | 17 | 2.2k 0.7× | 1.2k 0.6× | 904 0.8× | 305 0.3× | 1.8k 2.4× | 29 | 4.2k | ||
| Bastian von Tresckow Germany | 31 | 2.2k 0.7× | 2.2k 1.2× | 844 0.7× | 568 0.5× | 432 0.6× | 159 | 3.6k |
Countries citing papers authored by Simonetta Viviani
Since
Specialization
Citations
This map shows the geographic impact of Simonetta Viviani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simonetta Viviani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simonetta Viviani more than expected).
Fields of papers citing papers by Simonetta Viviani
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Simonetta Viviani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simonetta Viviani. The network helps show where Simonetta Viviani may publish in the future.
Co-authorship network of co-authors of Simonetta Viviani
This figure shows the co-authorship network connecting the top 25 collaborators of Simonetta Viviani. A scholar is included among the top collaborators of Simonetta Viviani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simonetta Viviani. Simonetta Viviani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Viviani, Simonetta, Chiara Pavoni, Sally F. Barrington, et al.. (2025). Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials. Blood Cancer Journal. 15(1). 165–165.
2.
Guidetti, Anna, Arabella Mazzocchi, Rosalba Miceli, et al.. (2017). Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research. 62. 91–97.
3.
Viviani, Simonetta, Valentina Tabanelli, & Stefano Pileri. (2017). The Pathobiology and Treatment of Hodgkin Lymphoma. Where do We go from Gianni Bonadonna's Lesson?. Tumori Journal. 103(2). 101–113.
4.
Eichenauer, Dennis A., Ingrid Becker, Ina Monsef, et al.. (2017). Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 102(10). 1748–1757.
5.
Sweetenham, John, Jan Walewski, Tamás Masszi, et al.. (2016). Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biology of Blood and Marrow Transplantation. 22(3). S36–S37.
6.
Sweetenham, John, Jan Walewski, Auayporn Nademanee, et al.. (2015). Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Blood. 126(23). 3172–3172.
7.
Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2014). Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research. 20(22). 5641–5651.
8.
Zinzani, Pier Luigi, Simonetta Viviani, Umberto Vitolo, et al.. (2013). Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 98(8). 1232–1236.
9.
Viviani, Simonetta, Pier Luigi Zinzani, Alessandro Rambaldi, et al.. (2011). ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. New England Journal of Medicine. 365(3). 203–212.
10.
Guidetti, Anna, Silvia L. Locatelli, Simonetta Viviani, et al.. (2011). Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,. Blood. 118(21). 3705–3705.
11.
Gallamini, Andrea, Martin Hutchings, Luigi Rigacci, et al.. (2007). Early Interim 2-[ 18 F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. Journal of Clinical Oncology. 25(24). 3746–3752.
12.
Bonadonna, Gianni, Simonetta Viviani, V. Bonfante, Alessandro M. Gianni, & Pinuccia Valagussa. (2005). Survival in Hodgkin’s disease patients – Report of 25 years of experience at the Milan Cancer Institute. European Journal of Cancer. 41(7). 998–1006.
13.
Bonfante, V., Simonetta Viviani, Liliana Devizzi, et al.. (2001). High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.. PubMed. 64. 51–5.
14.
Lissoni, Paolo, F Brivio, Simonetta Viviani, & Luca Fumagalli. (1999). Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?. PubMed. 13(2). 110–4.
15.
Lissoni, P., Silvia Bolis, Mario Mandalà, et al.. (1999). Blood Concentrations of Tumor Necrosis Factor-Alpha in Malignant Lymphomas and Their Decrease as a Predictor of Disease Control in Response to Low-Dose Subcutaneous Immunotherapy with Interleukin-2. The International Journal of Biological Markers. 14(3). 167–171.
16.
Santoro, Armando, V. Bonfante, Simonetta Viviani, et al.. (1997). Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early-stage Hodgkin's disease (HD): 5-year results of a randomized trial. European Journal of Cancer. 33. S262–S262.
17.
Viviani, Simonetta, V. Bonfante, M. Zanini, et al.. (1996). Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.. Journal of Clinical Oncology. 14(5). 1421–1430.
18.
Zanini, M., Simonetta Viviani, Armando Santoro, et al.. (1994). Extended-field radiotherapy in favorable stage IA–IIA Hodgkin's disease (Prognostic role of stage). International Journal of Radiation Oncology*Biology*Physics. 30(4). 813–819.
19.
Viviani, Simonetta, Attilio Orazi, Gabriella Sozzi, et al.. (1990). Preliminary Studies on Melatonin in the Treatment of Myelodysplastic Syndromes Following Cancer Chemotherapy. Journal of Pineal Research. 8(4). 347–354.
20.
Lissoni, Paolo, Sandro Barni, Franco Rovelli, et al.. (1990). The biological significance of soluble interleukin-2 receptors in solid tumors. European Journal of Cancer and Clinical Oncology. 26(1). 33–36.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eva Cavallin‐Ståhl Breakdown of academic impact, for papers by Francesco d’Amore Breakdown of academic impact, for papers by Peter Borchmann Breakdown of academic impact, for papers by Michael L. Grossbard Breakdown of academic impact, for papers by A. Z. S. Rohatiner Breakdown of academic impact, for papers by Franca Fossati‐Bellani Breakdown of academic impact, for papers by Gustaaf W. van Imhoff Breakdown of academic impact, for papers by Arne Kolstad Breakdown of academic impact, for papers by J. Rosenberg Breakdown of academic impact, for papers by Bastian von Tresckow